Hyperfine (HYPR) Net Income towards Common Stockholders (2021 - 2026)
Hyperfine's (HYPR) quarterly Net Income towards Common Stockholders came in at -$8.6 million in Q1 2026, up 8.44% YoY from -$8.0 million in Q1 2025, and down 45.86% on a QoQ basis from -$5.9 million in Q4 2025.
Hyperfine (HYPR) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Hyperfine (HYPR) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$8.6 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 8.44% year-over-year to -$8.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$34.8 million (up 13.68% YoY) and the FY2025 annual result came in at -$35.6 million, up 12.64% from the prior year.
- Net Income towards Common Stockholders declined to -$8.6 million in Q1 2026, from -$5.9 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$5.9 million in Q4 2025 to a low of -$23.8 million in Q1 2022.
- A 5-year average of -$11.9 million and a median of -$10.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders sank 205.04% — and 2023, when it surged 54.07%.
- Tracing HYPR's Net Income towards Common Stockholders over 5 years: stood at -$13.1 million in 2022, then gained by 18.19% to -$10.7 million in 2023, then rose by 2.75% to -$10.4 million in 2024, then surged by 43.1% to -$5.9 million in 2025, then slumped by 45.86% to -$8.6 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$8.6 million (Q1 2026), -$5.9 million (Q4 2025), and -$11.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | 907.00 Mn |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 621.86 Mn |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Hyperfine | 88.57 Mn | 43.81 Mn | 1.98 Mn | -9.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.30 Mn |
| Mar 31, 2026 | -8.62 Mn |
| Dec 31, 2025 | -5.91 Mn |
| Sep 30, 2025 | -11.02 Mn |
| Jun 30, 2025 | -9.23 Mn |
| Mar 31, 2025 | -9.42 Mn |
| Dec 31, 2024 | -10.39 Mn |
| Sep 30, 2024 | -10.33 Mn |
| Jun 30, 2024 | -10.16 Mn |
| Mar 31, 2024 | -9.85 Mn |
| Dec 31, 2023 | -10.68 Mn |
| Sep 30, 2023 | -10.76 Mn |
| Jun 30, 2023 | -10.64 Mn |
| Mar 31, 2023 | -12.16 Mn |
| Dec 31, 2022 | -13.06 Mn |
| Sep 30, 2022 | -13.17 Mn |
| Jun 30, 2022 | -23.16 Mn |
| Mar 31, 2022 | -23.78 Mn |
| Dec 31, 2021 | -26.09 Mn |
| Sep 30, 2021 | -16.39 Mn |